Company Overview and News

 
Global Geoscience Announces Successful Completion of Phase 1 of Rhyolite Ridge PFS Demonstrating a Clear Path Forward

2018-05-23 globenewswire
SYDNEY, Australia, May 23, 2018 (GLOBE NEWSWIRE) -- Australian-based lithium-boron mine developer Global Geoscience Limited (“Global” or the “Company”) (ASX:GSC) today announced the results of the first phase of the Pre-Feasibility Study (“PFS”) for the 100%-owned Rhyolite Ridge Lithium-Boron Project in Nevada, USA.

 
Optimisation Success Leads to Further Significant Reductions in Leach Time and Acid Consumption

2018-05-03 globenewswire
SYDNEY, Australia, May 02, 2018 (GLOBE NEWSWIRE) -- Australian-based lithium-boron mine developer Global Geoscience Limited (“Global” or the “Company”) (ASX:GSC) today announced the results of its latest acid-leach testwork from the 100%-owned Rhyolite Ridge Lithium-Boron Project in Nevada, USA. The latest vat leach testwork has shown that over 90% of the lithium and boron was extracted into solution in less than seven days.

 
Piedmont Lithium: Busy Few Months Ahead With Full Nasdaq Listing Any Day Now

2018-04-06 seekingalpha
Worries have come from Wall Street, which has no track record in calling the future of lithium, while the industry frets about lack of supply.

 
Piedmont Lithium Cash Infusion Will Speed Development Process And Extend Cash Runway

2017-11-01 seekingalpha
Assay results indicate 4 kilometers of mineralization at shallow depths, open on trend and at depth.

1
Piedmont Mining Progresses Project, Gains US Listing And Raises New Equity

2017-10-31 seekingalpha
Equity funding in Australia raises US$12.4m increasing market float by 22%, leaves company with market cap of US$86.6m and US$13.9m reserves.

 
Global Geoscience readies to advance lithium-boron deposit in Nevada

2017-09-26 proactiveinvestors.com.au
Global Geoscience Ltd (ASX:GSC) remains focused on the wholly-owned Rhyolite Ridge project located in Nevada, U.S., which is a large, shallow lithium-boron deposit.

 
Director Declaration

2017-05-24 londonstockexchange
In accordance with Listing Rule 9.6.14, Hunting hereby notifies that John Hofmeister, non-executive Director, was appointed as a Director of Global Geoscience Limited on 23 May 2017.

 
No swansong for Australia Post boss Ahmed Fahour at Senate estimates hearing

2017-05-23 smh.com.au
Our chief postie, Ahmed Fahour, will be a no-show at Wednesday afternoon's Senate estimates committee hearing – which is a pity considering the ratings generated by his previous appearance.

 
No swansong for Australia Post boss Ahmed Fahour at Senate estimates hearing

2017-05-23 theage.com.au
Our chief postie, Ahmed Fahour, will be a no-show at Wednesday afternoon's Senate estimates committee hearing – which is a pity considering the ratings generated by his previous appearance.

 
Global Geoscience shares continue to prevail

2017-05-19 proactiveinvestors.com.au
Global Geoscience (ASX:GSC) shares have proven resilient over recent days, a period where most ASX companies have struggled.

 
Global Geoscience to reveal lithium metallurgy results

2017-04-28 proactiveinvestors.com.au
Global Geoscience (ASX:GSC) has been granted a trading halt by the ASX, pending details of metallurgy results for the Rhyolite Ridge Lithium-Boron Project.

 
Global Geoscience reveals maiden resource for lithium project in Nevada

2016-10-14 proactiveinvestors.com.au
The total indicated and inferred resource is 393 million tonnes at 0.9% lithium carbonate, 2.9% boric acid and 1.7% potassium sulphate (1.2% lithium carbonate equivalent). This equates to 3.4 million tonnes of lithium carbonate contained within the resource. The mineral resource remains open to the north, south and east and has a significant potential to expand. North Basin, where the company recently obtained results for twenty historic drill holes, is not included in the resource estimate.

 
Global Geoscience Ltd reviews thick zones of lithium in Nevada

2016-10-07 proactiveinvestors.com.au
Global Geoscience Ltd (ASX:GSC) has analysed drill results showing thick, shallow zones of lithium-boron mineralisation over five square kilometres at the Rhyolite Ridge project in Nevada, U.S. The intersections include 33 metres at 1.22% lithium and 0.38% boron from 15 metres and 67 metres at 0.88 % lithium and 0.49% boron from 24 metres. The drill results were from historic exploration completed at North Basin by US Borax during the 1980’s, using a combination of rotary and percussion drilling methods.

 
Global Geoscience Ltd to update on lithium-boron resource

2016-10-07 proactiveinvestors.com.au
Global Geoscience Ltd (ASX:GSC) has been granted a trading halt by the ASX this morning, with its shares placed in pre-open. GSC requested the halt pending details in relation to a resource estimate for the Rhyolite Ridge Lithium-Boron Project in Nevada, U.S. The halt will remain in place until the opening of trade on Monday 10th October 2016, or earlier if an announcement is made to the market.

 
Global Geoscience Ltd to update on lithium-boron resource

2016-10-06 proactiveinvestors.com.au
Global Geoscience Ltd (ASX:GSC) has been granted a trading halt by the ASX this morning, with its shares placed in pre-open. GSC requested the halt pending details in relation to a resource estimate for the Rhyolite Ridge Lithium-Boron Project in Nevada, U.S. The halt will remain in place until the opening of trade on Monday 10th October 2016, or earlier if an announcement is made to the market.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...